
Pharmaceutical Executive
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.

Pharmaceutical Executive
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.

Pharmaceutical Executive
Policymakers seek to limit prescribing while also encouraging innovative R&D.

Pharmaceutical Executive
Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.








Pharmaceutical Executive
How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

Pharmaceutical Executive
Altruism and self-interest are at the heart of European thinking on neglected diseases.

Pharmaceutical Executive
The practice’s emerging-if improbable-cost-saving potential.

Pharmaceutical Executive
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.





Pharmaceutical Executive
Europe’s contrasting views on rare disease drugs - one bashing pricing abuses, the other extolling their public health virtues - could ultimately leave these products out in the cold.

Pharmaceutical Executive
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.

As US pharma continues to ponder its “winter of discontent”, the question that leaders of industry have to be asking themselves is, “How did things get this bad?” Tom Norton reports.







